Leucomax

group Hematopoiesis stimulants

Leukomax is a drug that belongs to the group of hematopoiesis stimulants. It is used to treat various pathological conditions that are accompanied by disorders of myeloid hematopoiesis. The drug helps stimulate the release of hematopoietic precursor cells from the bone marrow into the peripheral blood, which facilitates their isolation by leukapheresis and transplantation.

Leucomax is manufactured in Switzerland by Novartis, Sandoz Pharma Ltd. and Schering-Plough, and in the United States by Schering-Plough. The active ingredient of the drug is molgramostim.

The drug is available in the form of lyophilized powder for the preparation of injection solution and powder for the preparation of injection solution. Leukomax is used for the treatment of leukopenia in various pathological conditions, as well as as primary prevention of neutropenia and neutropenic infection with a high risk of its development after chemotherapy.

The drug is also used to reduce the myelotoxic effect of antiviral drugs in the treatment of cytomegalovirus infection in patients with AIDS and to restore myeloid hematopoiesis during bone marrow transplantation.

Despite the effectiveness of the drug, it has contraindications. Leukomax is not recommended for use in case of hypersensitivity to the active substance, myeloid leukemia, lung diseases, autoimmune diseases, pregnancy and breastfeeding.

In addition, the drug has side effects that can manifest itself in the form of increased body temperature, dyspeptic symptoms, abdominal pain, shortness of breath, weakness, sweating, ossalgia, myalgia, headaches, dizziness, fainting, paresis, cerebrovascular accident, hypotension, arrhythmias, acute heart failure, pericarditis, thrombocytopenia and other symptoms.

In case of an overdose of the drug, symptoms such as tachycardia, hypotension, fever, weakness, headaches and myalgia may occur. In such cases, symptomatic treatment is necessary.

Injections of Leucomax should be carried out only in a specialized hospital; when the drug is first administered, the possibility of developing life-threatening complications should be taken into account, therefore it is necessary to carefully monitor the patient’s condition and monitor blood counts.

In general, the use of Leucomax should be carried out under the strict supervision of a physician and in accordance with his recommendations. Patients prescribed this drug should be attentive to their condition and if any side effects occur, be sure to notify the doctor.